At the International Psoriasis Council (IPC), we’re a passionate community of researchers and physician experts who share a common goal: improving the health and well-being of people with psoriasis worldwide. We understand the challenges people with psoriasis face and are committed to making a difference.
Our focus is educating health care professionals in psoriasis care management, which aligns with the World Health Organization’s call for improved physician training. We offer clinicians a range of free resources, tools, and information, including live education sessions, webinars, and on-demand videos featuring IPC Board Members and Councilors, renowned opinion leaders in psoriasis.
We are also highly committed to enhancing patient outcomes worldwide by prioritizing research efforts. Our focus is on strengthening the capacity of researchers, promoting collaboration through international partnerships, stakeholder involvement, and evidence-based research, and offering innovative programs and events that support the growth and development of early-career researchers. Together, we can achieve our ultimate goal of improving health care outcomes for all.
IPC was established in 2004 as a United States-based nonprofit organization led by a Board of Directors and supported by a dedicated staff. Our vision is to create a world free of the burden of psoriasis, where people with psoriasis worldwide have access to the best available care and are empowered to lead healthy, fulfilling lives. Our mission is to improve the health and well-being of people with psoriasis and associated diseases worldwide through education, research, and advocacy. We’re excited about the future and look forward to making a positive impact.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
